Sustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells Due to SOCS-3 Epigenetic Silencing

Gastroenterology

Volumn 132, Issue 1, 2007, Pages 384-396

  Isomoto, Hajime ^a   Mott, Justin L ^a   Kobayashi, Shogo ^a   Werneburg, Nathan W ^a   Bronk, Steve F ^a   Haan, Serge ^b   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; INTERLEUKIN 6; PROTEIN MCL 1; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER GENE THERAPY; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DEMETHYLATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; EPIGENETICS; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 33846200831     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.10.037     Document Type: Article

References (57)

1. Gores G.J. Cholangiocarcinoma: current concepts and insights. Hepatology 37 (2003) 961-969
2. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A., Hultcrantz R., Lindgren S., Prytz H., Sandberg-Gertzen H., Almer S., Granath F., and Broome U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (2002) 321-327
3. Tocchi A., Mazzoni G., Liotta G., Lepre L., Cassini D., and Miccini M. Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg 234 (2001) 210-214
4. Lazaridis K.N., and Gores G.J. Cholangiocarcinoma. Gastroenterology 128 (2005) 1655-1667
5. Garcea G., Dennison A.R., Steward W.P., and Berry D.P. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 5 (2005) 514-529
6. Peek Jr. R.M., and Crabtree J.E. Helicobacter infection and gastric neoplasia. J Pathol 208 (2006) 233-248
7. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287 (2004) G7-G17
8. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
9. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41 (2005) 5-15
10. Nakanuma Y., Harada K., Ishikawa A., Zen Y., and Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10 (2003) 265-281
11. Hideshima T., Podar K., Chauhan D., and Anderson K.C. Cytokines and signal transduction. Best Pract Res Clin Haematol 18 (2005) 509-524
12. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4 (2004) 11-22
13. Goydos J.S., Brumfield A.M., Frezza E., Booth A., Lotze M.T., and Carty S.E. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227 (1998) 398-404
14. Park J., Tadlock L., Gores G.J., and Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30 (1999) 1128-1133
15. Okada K., Shimizu Y., Nambu S., Higuchi K., and Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 9 (1994) 462-467
16. Sugawara H., Yasoshima M., Katayanagi K., Kono N., Watanabe Y., Harada K., and Nakanuma Y. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 33 (1998) 145-153
17. Hodge D.R., Hurt E.M., and Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41 (2005) 2502-2512
18. Isomoto H., Kobayashi S., Werneburg N.W., Bronk S.F., Guicciardi M.E., Frank D.A., and Gores G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42 (2005) 1329-1338
19. Kobayashi S., Werneburg N.W., Bronk S.F., Kaufmann S.H., and Gores G.J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128 (2005) 2054-2065
20. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., Kaufmann S.H., and Gores G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64 (2004) 3517-3524
21. Trikha M., Corringham R., Klein B., and Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9 (2003) 4653-4665
22. Almasan A., and Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14 (2003) 337-348
23. Greenhalgh C.J., Miller M.E., Hilton D.J., and Lund P.K. Suppressors of cytokine signaling: relevance to gastrointestinal function and disease. Gastroenterology 123 (2002) 2064-2081
24. Kubo M., Hanada T., and Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 4 (2003) 1169-1176
25. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
26. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., and Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4 (2003) 540-545
27. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., Rutschman R., and Murray P.J. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4 (2003) 546-550
28. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., and Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275 (2000) 12848-12856
29. Takai D., and Jones P.A. The CpG island searcher: a new WWW resource. In Silico Biol 3 (2003) 235-240
30. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., Costello J.F., McCormick F., and Jablons D.M. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 100 (2003) 14133-14138
31. Weber A., Hengge U.R., Bardenheuer W., Tischoff I., Sommerer F., Markwarth A., Dietz A., Wittekind C., and Tannapfel A. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24 (2005) 6699-6708
32. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., and Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24 (2005) 6406-6417
33. Rashid A., and Issa J.P. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 127 (2004) 1578-1588
34. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
35. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
36. Knuth A., Gabbert H., Dippold W., Klein O., Sachsse W., Bitter-Suermann D., Prellwitz W., and Meyer zum Buschenfelde K.H. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1 (1985) 579-596
37. Shimizu Y., Demetris A.J., Gollin S.M., Storto P.D., Bedford H.M., Altarac S., Iwatsuki S., Herberman R.B., and Whiteside T.L. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 52 (1992) 252-260
38. Park J., Gores G.J., and Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology 29 (1999) 1037-1043
39. Hortner M., Nielsch U., Mayr L.M., Heinrich P.C., and Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem 269 (2002) 2516-2526
40. Dunn S.L., Bjornholm M., Bates S.H., Chen Z., Seifert M., and Myers Jr. M.G. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 19 (2005) 925-938
41. Hamanaka I., Saito Y., Yasukawa H., Kishimoto I., Kuwahara K., Miyamoto Y., Harada M., Ogawa E., Kajiyama N., Takahashi N., Izumi T., Kawakami R., Masuda I., Yoshimura A., and Nakao K. Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo. Circ Res 88 (2001) 727-732
42. Park S.M., Schickel R., and Peter M.E. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 17 (2005) 610-616
43. Toyota M., and Issa J.P. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32 (2005) 521-530
44. Kang G.H., Lee H.J., Hwang K.S., Lee S., Kim J.H., and Kim J.S. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 163 (2003) 1551-1556
45. Hodge D.R., Xiao W., Clausen P.A., Heidecker G., Szyf M., and Farrar W.L. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 276 (2001) 39508-39511
46. Hodge D.R., Peng B., Cherry J.C., Hurt E.M., Fox S.D., Kelley J.A., Munroe D.J., and Farrar W.L. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65 (2005) 4673-4682
47. Agirre X., Novo F.J., Calasanz M.J., Larrayoz M.J., Lahortiga I., Valganon M., Garcia-Delgado M., and Vizmanos J.L. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 38 (2003) 201-208
48. Culig Z., Steiner H., Bartsch G., and Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95 (2005) 497-505
49. Zhan M., and Han Z.C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19 (2004) 915-923
50. Yoon J.H., Werneburg N.W., Higuchi H., Canbay A.E., Kaufmann S.H., Akgul C., Edwards S.W., and Gores G.J. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 62 (2002) 6500-6505
51. Meng F., Yamagiwa Y., Ueno Y., and Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 44 (2006) 1055-1065
52. Ishimura N., Isomoto H., Bronk S.F., and Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290 (2006) G129-G136
53. Eramo A., Pallini R., Lotti F., Sette G., Patti M., Bartucci M., Ricci-Vitiani L., Signore M., Stassi G., Larocca L.M., Crino L., Peschle C., and De Maria R. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 65 (2005) 11469-11477
54. Horak P., Pils D., Haller G., Pribill I., Roessler M., Tomek S., Horvat R., Zeillinger R., Zielinski C., and Krainer M. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3 (2005) 335-343
55. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., and Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20 (2001) 5865-5877
56. Lyko F., and Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97 (2005) 1498-1506
57. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5 (2006) 37-50